Schering AG/Chiron Betaseron Label Expansion For Early MS Expected By Q4
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Schering AG expects expanded approval of its multiple sclerosis therapy Betaseron in the fourth quarter to allow earlier use for newly emergent disease